Cidara Therapeutics Named a San Diego Metro Area Top Workplace for Second Consecutive Year

News Release

Cidara Therapeutics Named a San Diego Metro Area Top Workplace for Second Consecutive Year

November 12, 2018 at 8:00 AM EST

Employee feedback places Cidara among top 15 small companies in
the area

SAN DIEGO--(BUSINESS WIRE)--Nov. 12, 2018--
Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company
developing novel anti-infectives including immunotherapies, today
announced that it has been named a Top Workplace by The San Diego
Union-Tribune for the second consecutive year. Cidara ranked among the
top 15 small companies, and the number one ranked biotech in the small
company category, in the San Diego Metro Area.

“We are once again honored to be recognized as a top workplace by our
employees, whose feedback reflects our commitment to nurturing a
positive work environment where we are true to our values and advocate
for integrity, collaboration, urgency, accountability and courage,” said
Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.
“We foster innovation by challenging the status quo, encouraging new
ideas and enabling autonomy, all while working with conviction at a pace
that reflects the needs of the patients we serve.”

Top Workplace lists are based solely on employee feedback gathered
through a third-party survey administered by Energage, LLC, a leading
provider of technology-based employee engagement tools. The anonymous
survey measures several aspects of workplace culture, including
alignment, execution, and connection. According to Energage, 100 percent
of Cidara employees participated in the 2018 survey.

From its inception, Cidara leadership identified the core principles
that would drive the company’s culture. From there, the entire
organization fleshed out these principles to make that vision a reality,
and to identify and articulate the common behaviors under each of these
principles for which they would be accountable. The company continues to
build and sustain this strong, principle-based culture as they work to
bring lifesaving anti-infectives to patients.

Cidara is a clinical-stage biotechnology company focused on developing
new anti-infectives that have the potential to transform the standard of
care and save or improve patients’ lives. The company is currently
advancing its novel echinocandin antifungal, rezafungin acetate, in a
Phase 3 clinical trial in the treatment of candidemia and invasive
candidiasis and plans to initiate a second Phase 3 trial in the
prophylaxis of invasive fungal infections. Rezafungin has improved
pharmacokinetics compared to existing echinocandins and the potential
for expanded utility across patient settings. It is the only once-weekly
product candidate in development for the treatment and prevention of
life-threatening invasive fungal infections. Cidara also is leveraging
its novel Cloudbreak™ platform to develop antibody-drug conjugates for
the treatment of serious viral and Gram-negative bacterial infections.
Cloudbreak is the first immunotherapy discovery platform designed
specifically to create compounds that directly kill pathogens and also
direct a patient’s immune cells to attack and eliminate bacterial,
fungal or viral pathogens. Cidara is headquartered in San Diego,
California. For more information, please visit www.cidara.com.

Tool Kit

About Cidara

Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives and immunotherapies that have the potential to transform the standard of care and save or improve patients' lives.
Learn more >>